Conformational diseases: Looking into the eyes

Brain Research Bulletin

Volumn 81, Issue 1, 2010, Pages 12-24

  Surguchev, Alexei ^a   Surguchov, Andrei ^b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macula degeneration; Cataract; Lens; Protein aggregation; Retina; Rhodopsin

Indexed keywords

4 PHENYLBUTYRIC ACID; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; ANSAMYCIN DERIVATIVE; BETA SHEET BREAKER; CHAPERONE; CRYSTALLIN; GELDANAMYCIN; LENS PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PRION PROTEIN; PROTEASOME INHIBITOR; RADICICOL; RHODOPSIN; SALICYLATE SODIUM; TANESPIMYCIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOIDOSIS; CATARACT; CELLULAR IMMUNITY; CILIARY BODY; CORNEA DISEASE; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG SCREENING; DRUSEN; EYE CONFORMATIONAL DISEASE; EYE DISEASE; GENE MUTATION; GENE THERAPY; GLAUCOMA; HUMAN; LIGAND BINDING; MUTATIONAL ANALYSIS; NONHUMAN; OPTIC NERVE DISEASE; PATHOGENESIS; PHOTORECEPTOR CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; STRESS; STRUCTURE ACTIVITY RELATION; THALASSEMIA; TRABECULAR MESHWORK; VITREORETINOPATHY;

ANIMALS; EYE DISEASES; HUMANS; MODELS, BIOLOGICAL; PROTEOSTASIS DEFICIENCIES;

EID: 71349083669     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.09.015     Document Type: Review

References (159)

1. Abrahamson M., and Grubb A. Increased body temperature accelerates aggregation of the Leu-68-->Gln mutant cystatin C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 1416-1420
2. Anderson D.H., Talaga K.C., Rivest A.J., Barron E., Hageman G.S., and Johnson L.V. Characterization of β-amyloid assemblies in druzen: the deposits associated with aging and aged-related macular degeneration. Exp. Eye Res. 78 (2004) 243-256
3. Anfinsen C.B. The formation and stabilization of protein structure. The sixth jubilee lecture. Biochem. J. 128 (1972) 737-749
4. Anfinsen C.B. Principles that govern the folding of protein chains. Science 181 (1973) 223-230
5. Araki-Sasaki K., Ando Y., Nakamura M., Kitagawa K., Ikemizu S., Kawaji T., Yamashita T., Ueda M., Hirano K., Yamada M., Matsumoto K., Kinoshita S., and Tanihara H. Lactoferrin Glu561Asp facilitates secondary amyloidosis in the cornea. Br. J. Ophthalmol. 89 (2005) 684-688
6. Balch W.E., Morimoto R.I., Dillin A., and Kelly J.W. Adapting proteostasis for disease intervention. Science 319 (2008) 916-919
7. Barghorn S., Davies P., and Mandelkow E. Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry 43 (2004) 1694-1703
8. Barouch F.C., Benson M.D., and Mukai S. Isolated vitreoretinal amyloidosis in the absence of transthyretin mutations. Arch. Ophthalmol. 122 (2004) 123-125
9. Batra-Safferling R., Abarca-Heidemann K., Körschen H.G., Tziatzios C., Stoldt M., Budyak I., Willbold D., Schwalbe H., Klein-Seetharaman J., and Kaupp U.B. Glutamic acid-rich proteins of rod photoreceptors are natively unfolded. J. Biol. Chem. 281 (2006) 1449-1460
10. Bhisitkul R.B., and Mukai S. Vitreous amyloidosis. In: Albert D.M., and Jakobiec F.A. (Eds). Principles and Practice of Ophthalmology. 2nd ed. (2000), WB Saunders, Philadelphia, PA 2530-2539
11. Booth D.R., Sunde Belotti M.V., Robinson C.V., Hutchinson W.L., Fraser P.E., Hawkins P.N., Dobson C.M., Radford S.E., Blake C.C., and Pepys M.B. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385 (1997) 787-793
12. Bornheim R., Müller M., Reuter U., Herrmann H., Büssow H., and Magin T.M. A dominant vimentin mutant upregulates Hsp70 and the activity of the ubiquitin-proteasome system, and causes posterior cataracts in transgenic mice. J. Cell Sci. 121 (2008) 3737-3746
13. Bukau B., Weissman J., and Horwich A. Molecular chaperones and protein quality control. Cell 125 (2006) 443-451
14. Carrell R.W., and Lomas D.A. Conformational disease. Lancet 350 (1997) 134-138
15. Chapple J.P., and Cheetham M.E. The chaperone environment at the cytoplasmic face of the endoplasmic reticulum can modulate rhodopsin processing and inclusion formation. J. Biol. Chem. 278 (2003) 19087-19094
16. Chapple J.P., Grayson C., Hardcastle A.J., Saliba R.S., vanderSpuy J., and Cheesam M.E. Unfolding retinal dystrophies: a role for molecular chaperones?. Trends Mol. Med. 7 (2001) 414-421
17. Char D.H., Crawford J.B., Howes E., and Carolan J.A. Amyloid mass of the ciliary body. Arch. Ophthalmol. 124 (2006) 908-910
18. Chen Y.C., Reid G.E., Simpson R.J., and Truscott R.J. Molecular evidence for the involvement of alpha crystallin in the coloration/crosslinking of crystallins in age related nuclear cataract. Exp. Eye Res. 65 (1997) 835-840
19. Chesebro B., Race R., and Kercher L. Scrapie pathogenesis in brain and retina: effects of prion protein expression in neurons and astrocytes. J. Neurovirol. 11 (2005) 476-480
20. Chiti F., and Dobson C.M. Protein misfolding, functional amyloid, and human disease. Ann. Rev. Biochem. 75 (2006) 333-366
21. Clout N.J., and Hohenester E. A model of FAS1 domain 4 of the corneal protein βig-h3 gives a clearer view on corneal dystrophies. Mol. Vis. 9 (2003) 440-448
22. Conchillo-Solé O., de Groot N.S., Avilés F.X., Vendrell J., Daura X., and Ventura S. AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides. BMC Bioinformatics 8 (2007) 65-81
23. Davidson W.S., Jonas A., Clayton D.F., and George J.M. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273 (1998) 9443-9449
24. DeLorenzi E., Giorgetti S., Grossi S., Merlini G., Caccialanza G., and Belotti V. Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a protein misfolding disease. Curr. Med. Chem. 204 (2004) 1065-1084
25. Derham B.K., and Harding J.J. Effects of modifications of α-crystallin on its chaperone and other properties. Biochem. J. 364 (2002) 711-717
26. Dill K.A., and Chan H.S. From Levinthal to pathways to funnels. Nat. Struct. Biol. 4 (1997) 10-19
27. Ding J., Lin J., Mace B.E., Herrmann R., Sullivan P., and Rickman C.B. Targeting age-related macular degeneration with AD based immunotherapies: anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res. 48 (2008) 339-345
28. Dobson C.M. Protein misfolding, evolution and disease. TIBS 24 (1999) 329-332
29. Dobson C.M. The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 356 (2001) 133-145
30. Dobson C.M. Protein-misfolding diseases: getting out of shape. Nature 418 (2002) 729-730
31. Dobson C.M. Protein folding and misfolding. Nature 426 (2003) 884-890
32. Dobson C.M. The generic nature of protein folding and misfolding. In: Atassi M.Z. (Ed). Protein Reviews (2006), Springer 21-41
33. Dunker A.K., Garner E., Guilliot S., Romero P., Albercht K., Hart J., Obradovic Z., Kissinger C., and Villafranca J.E. Protein disorder and the evolution of molecular recognition: theory, predictions and observations. Pac. Symp. Biocomput. 3 (1998) 473-484
34. Dunker A.K., Oldfield C.J., Meng.F J., Romero P., Yang J.Y., Chen J.W., Vacic V., Obradovic Z., and Uversky V.N. Unnfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics 16 Suppl. 2 (2008) S1
35. Dryja T.P., McGee T.L., Reichel E., Hahn L.B., Cowley G.S., Yandell D.W., Sandberg M.A., and Berson E.L. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 343 (1990) 364-366
36. Ecroyd H., and Carver J.A. Crystallin proteins and amyloid fibrils. Cell. Mol. Life Sci. 66 (2009) 62-81
37. Ellis R.J. Molecular chaperones: inside and outside the Anfinsen cage. Curr. Biol. 11 (2001) R1038-R1040
38. Ellis R.J. Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr. Opin. Struct. Biol. 11 (2001) 114-119
39. Ellis R.J., and Minton A.P. Join the crowd. Nature 425 (2003) 27-28
40. Estey T., Cantore M., Weston P.A., Carpenter J.F., Petrash J.M., and Vasiliou V. Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1. J. Biol. Chem. 282 (2007) 4382-4392
41. Fattal E., and Barratt G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br. J. Pharmacol. 157 (2009) 179-194
42. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
43. Fedorov N., and Baldwin T.O. Contribution of cotranslational folding to the rate of formation of native protein structure. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 1227-1231
44. Fernandez A., Kardos J., Scott L.R., Goto Y., and Berry R.S. Structural defects and the diagnosis of amyloidogenic propensity. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6446-6451
45. Findeis M.A. The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol. Ther. 116 (2007) 266-286
46. Fingert J.H., Stone E.M., Sheffield V.C., and Alward W.L. Myocilin glaucoma. Surv. Ophthalmol. 47 (2002) 547-561
47. Fink A.L. Natively unfolded proteins. Curr. Opin. Struct. Biol. 15 (2005) 35-41
48. Fink A.L. The aggregation and fibrillation of alpha-synuclein. Acc. Chem. Res. 39 (2006) 628-634
49. Flaugh S.L., Kosinski-Collins M.S., and King J. Contributions of hydrophobic domain interface interactions to the folding and stability of human gammaD-crystallin. Protein Sci. 14 (2005) 569-581
50. Foster J.D., Fraser H., and Bruce M.E. Retinopathy in mice with experimental scrapie. Neuropathol. Appl. Neurobiol. 12 (1986) 185-196
51. Fraunfelder F.W. Liquid nitrogen cryotherapy for conjunctival amyloidosis. Arch. Ophalmol. 127 (2009) 645-648
52. Frederikse P.H., Garland D., Zigler Jr. J.S., and Piatigorsky J. Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J. Biol. Chem. 271 (1996) 10169-10174
53. Frederikse P.H., Zigler Jr. S.J., Farnsworth P.N., and Carper D.A. Prion protein expression in mammalian lenses. Curr. Eye Res. 20 (2000) 137-143
54. Fujikake N., Nagai Y., Popiel H.A., Okamoto Y., Yamaguchi M., and Toda T. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem. 283 (2008) 26188-26197
55. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., and Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4 (2002) 160-164
56. Goenka S., Raman B., Ramakrishna T., and Rao C.M. Unfolding and refolding of a quinone oxidoreductase: α-crystallin, a molecular chaperone, assists its reactivation. Biochem. J. 359 (2001) 547-556
57. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 426 (2003) 895-899
58. Gould D.B., Reedy M., Wilson L.A., Smith R.S., Johnson R.L., and John S.W.M. Mutant myocilin nonsecretion in vivo is not sufficient to cause glaucoma. Mol. Cell. Biol. 26 (2006) 8427-8436
59. Graw J. Cataract mutations and lens development. Prog. Retin. Eye Res. 18 (1999) 235-267
60. Graw J. Congenital hereditary cataracts. Int. J. Dev. Biol. 48 (2004) 1031-1044
61. Graw J. Genetics of crystallins: cataract and beyond. Exp. Eye Res. 88 (2009) 173-189
62. Greenlee J.J., Hamir A.N., and West Greenlee M.H. Abnormal prion accumulation associated with retinal pathology in experimentally inoculated scrapie-affected sheep. Vet. Pathol. 43 (2006) 733-739
63. Guo L., Salt T.E., Luong V., Wood N., Cheung W., Maass A., Ferrari G., Russo-Marie F., Sillito A.M., Cheetham M.E., Moss S.E., Fitzke F.W., and Cordeiro M.F. Targeting amyloid-beta in glaucoma treatment. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 13444-13449
64. Guo L., Salt T.E., Luong V., Wood N., Cheung W., Maass A., Ferrari G., Russo-Marie F., Sillito A.M., Haas A.L., and Siepman T.J. Pathways of ubiquitin conjugation. FASEB J. 11 (1997) 1257-1268
65. Haraoka K., Ando Y., Ando E., Sandgren O., Hirata A., Nakamura M., Terazaki H., Tajiri T., Tanoue Y., Sun X., Okabe H., and Tanihara H. Amyloid deposition in ocular tissues of patients with familial amyloidotic polyneuropathy (FAP). Amyloid 9 (2002) 183-189
66. Harding J.J. Conformational changes in human lens proteins in cataract. Biochem. J. 129 (1972) 97-100
67. Harding J.J. Viewing molecular mechanisms of ageing through a lens. Ageing Res. Rev. 1 (2002) 465-479
68. Harmeier A., Wozny C., Rost B.R., Munter L.M., Hua H., Georgiev O., Beyermann M., Hildebrand P.W., Weise C., Schaffner W., Schmitz D., and Multhaup G. Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. J. Neurosci. 29 (2009) 7582-7590
69. Hatters D.M., Lindner R.A., Carver J.A., and Howlett G.J. The molecular chaperone α-crystallin, inhibits amyloid formation by apolipoprotein C-II. J. Biol. Chem. 276 (2001) 33755-33761
70. Head M.W., Northcott V., Rennison K., Ritchie D., McCardle L., Bunn T.J., McLennan N.F., Ironside J.W., Tullo A.B., and Bonshek R.E. Prion protein accumulation in eyes of patients with sporadic and variant Creutzfeldt-Jakob disease. Invest. Ophthalmol. Vis. Sci. 44 (2003) 342-346
71. Head M.W., Peden A.H., Yull H.M., Ritchie D.L., Bonshek R.E., Tullo A.B., and Ironside J.W. Abnormal prion protein in the retina of the most commonly occurring subtype of sporadic Creutzfeldt-Jakob disease. Br. J. Ophthalmol. 89 (2005) 1131-1133
72. Hogan R.N., Baringer J.R., and Prusiner S.B. Progressive retinal degeneration in scrapie-infected hamsters: a light and electron microscopic analysis. Lab. Invest. 44 (1981) 34-42
73. Hong S., Lee H.K., Kim C.Y., and Seong G.J. Identification and localization of α-synuclein in human cornea. Korean J. Ophthalmol. 22 (2008) 145-146
74. Huang A.J.W. Suppression of keratoepithelin and myocilin by small interfering RNA. Trans. Am. Ophthalmol. Soc. 105 (2007) 365-378
75. Hurle M.R., Helms L.R., Li L., Chan W., and Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 5446-5450
76. Illing M.E., Rajan R.S., Bence N.F., and Kopito R.R. A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. J. Biol. Chem. 277 (2002) 34150-34160
77. Jacobson N., Andrews M., Shepard A.R., Nishimura D., Searby C., Fingert J.H., Hageman G., Mullins R., Davidson B.L., Kwon Y.H., Alward W.L., Stone E.M., Clark A.F., and Sheffield V.C. Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured TM cells and in aqueous humor. Hum. Mol. Genet. 10 (2001) 117-125
78. Jaenicke R., and Slingsby C. Lens crystallins and their microbial homologs: structure, stability and function. Crit. Rev. Biochem. Mol. Biol. 36 (2001) 435-499
79. Johnston J.A., Ward C.L., and Kopito R.R. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143 (1998) 1883-1898
80. Jung J., Byeon I.J., Wang Y., King J., and Gronenborn A.M. The structure of the cataract-causing P23T mutant of human gammaD-crystallin exhibits distinctive local conformational and dynamic changes. Biochemistry 48 (2009) 2597-2609
81. Karring H., Thøgersen I.B., Klintworth G.K., Enghild J.J., and Møller-Pedersen T. Proteomic analysis of the soluble fraction from human corneal fibroblasts with reference to ocular transparency. Mol. Cell. Proteomics 3 (2004) 660-674
82. Kaushal S., and Khorana H.G. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa. Biochemistry 33 (1994) 6121-6128
83. Kawaji T., Ando Y., Ando E., Nakamura M., Hirata A., and Tanihara H.H. A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathy. Amyloid 11 (2004) 257-259
84. Kawasaki S., Nishida K., Quantock A.J., Dota A., Bennett K., and Kinoshita S. Amyloid and Pro501 Thr-mutated (beta)ig-h3 gene product colocalize in lattice corneal dystrophy type III. Am. J. Ophthalmol. 127 (1999) 456-458
85. Kawasaki Y., Kawagoe K., Chen C., Teruya K., Sakasegawa Y., and Doh-ura K. Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J. Virol. 81 (2007) 12889-12898
86. Kercher L., Favara C., Striebel J.F., LaCasse R., and Chesebro B. Prion protein expression differences in microglia and astroglia influence scrapie-induced neurodegeneration in the retina and brain of transgenic mice. J. Virol. 81 (2007) 10340-10351
87. Kivelä T., Tarkkanen A., Frangione B., Ghiso J., and Haltia M. Ocular amyloid deposition in familial amyloidosis finnish: an analysis of native and variant gelsolin in Meretoja's syndrome. Invest. Ophthalmol. Vis. Sci. 35 (1994) 3759-3769
88. Kontsekova E., Ivanovova N., Handzusova M., and Novak M. Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy. Cell. Mol. Neurobiol. 29 (2009) 793-798
89. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell. Biol. 10 (2000) 524-530
90. Kopito R.R., and Ron D. Conformational disease. Nat. Cell Biol. 2 (2000) E207-E209
91. Korvatska E., Munier F.L., Chaubert P., Wang M.X., Mashima Y., Yamada M., Uffer S., Zografos L., and Schorderet D.F. On the role of kerato-epithelin in the pathogenesis of 5q31-linked corneal dystrophies. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2213-2219
92. Kosmaoglou M., Schwarz N., Bett J.C., and Cheetham M.E. Molecular chaperones and photoreceptor function. Prog. Retin. Eye Res. 27 (2008) 434-449
93. Kosinski-Collins M.S., and King J. In vitro unfolding, refolding, and polymerization of human γD crystallin, a protein involved in cataract formation. Protein Sci. 12 (2003) 12480-12490
94. Krasheninnikov I.A., Komar A.A., and Adzhubei I.A. Nonuniform size distribution of nascent globin peptides, evidence for pause localization sites, and a cotranslational protein-folding model. J. Protein Chem. 10 (1991) 445-453
95. Leibovitch I., Selva D., Goldberg R.A., Sullivan T.J., Saeed P., Davis G., McCann J.D., McNab A., and Rootman J. Periocular and orbital amyloidosis: clinical characteristics, management, and outcome. Ophthalmology 113 (2006) 1657-1664
96. Lindner A.B., and Demarez A. Protein aggregation as a paradigm of ageing. Biochim. Biophys. Acta (2009) 10.1016/j.bbagen.2009.06.005
97. Luibl V., Isas J.M., Kayed R., Glabe C.G., Langen R., and Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J. Clin. Invest. 116 (2006) 378-385
98. Liu Y., and Vollrath D. Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma. Hum. Mol. Genet. 13 (2004) 1193-1204
99. Martínez-Navarrete G.C., Martín-Nieto J., Esteve-Rudd J., Angulo A., and Cuenca A.N. α-Synuclein gene expression profile in the retina of vertebrates. Mol. Vis. 13 (2007) 949-961
100. McCutchen S.L., Lai Z., Miroi G.J., Kelly J.W., and Colon W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34 (1995) 13527-13536
101. McKinnon S.J., Lehman D.M., Kerrigan-Baumrind L.A., Merges C.A., Pease M.E., Kerrigan D.F., Ransom N.L., Tahzib N.G., Reitsamer H.A., Levkovitch-Verbin H., Quigley H.A., and Zack D.J. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1077-1087
102. Meehan S., Berry Y., Luisi B., Dobson C.M., Carver J.A., and MacPhee C.E. Amyloid fibril formation by lens crystallin proteins and its implications for cataract formation. J. Biol. Chem. 279 (2004) 3413-3419
103. Mendes H.F., van der Spuy J., Chapple J.P., and Cheetham M.E. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol. Med. 11 (2005) 177-185
104. Mitraki A., Betton J.M., Desmadril M., and Yon J.M. Quasi-irreversibility in the unfolding-refolding transition of phosphoglycerate kinase induced by guanidine hydrochloride. Eur. J. Biochem. 163 (1987) 29-34
105. Muchowski P.J., Ramsden R., Nguyen Q.V., Arnett E.E., Greiling T.M., Anderson S.K., and Clark J.I. Noninvasive measurement of protein aggregation by mutant huntingtin fragments or α-synuclein in the lens. J. Biol. Chem. 283 (2008) 6330-6336
106. Munier F.L., Korvatska E., Djemai A., Le Paslier D., Zografos L., Pescia G., and Schorderet D.F. Kerato-epithelin mutations in four 5q31-linked corneal dystrophies. Nat. Genet. 15 (1997) 247-251
107. Nguyen V.T., Hwang T.N., Shamie N., Chuck R.S., and McCulley T.J. Amyloidosis-associated neurotrophic keratopathy precipitated by overcorrected blepharoptosis. Cornea 28 (2009) 575-576
108. O'Hearn T.M., Fawzi A., He S., Rao N.A., and Lim J.I. Early onset vitreous amyloidosis in familial amyloidotic polyneuropathy with a transthyretin Glu54Gly mutation is associated with elevated vitreous VEGF. Br. J. Ophthalmol. 91 (2007) 1607-1609
109. Papanikolopoulou K., Mills-Henry I., Thol S.L., Wang Y., Gross A.A.R., Kirschner D.A., Decatur S.M., and King J. Formation of amyloid fibrils in vitro by human γD-crystallin and its isolated domains. Mol. Vis. 14 (2008) 81-89
110. Pawar A.P., Dubay K.F., Zurdo J., Chiti F., Vendruscolo M., and Dobson C.M. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 350 (2005) 379-392
111. Perng M.D., Zhang Q., and Quinlan R.A. Insights into the beaded filament of the eye lens. Exp. Cell Res. 313 (2007) 2180-2188
112. Perrin R.J., Woods W.S., Clayton D.F., and George J.M. Interaction of human α-synuclein and Parkinson's disease variants with phospholipids: Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275 (2000) 34393-34398
113. Powers E.T., Morimoto R.I., Dillin A., Kelly J.W., and Balch W.E. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78 (2009) 959-991
114. Prusiner S.B. Prions causing degenerative neurological diseases. Annu. Rev. Med. 38 (1987) 381-398
115. Rajawat Y.S., Hilioti Z., and Bossis I. Aging: central role for autophagy and the lysosomal degradative system. Ageing Res. Rev. 8 (2009) 199-213
116. Rami A. Autophagy in neurodegeneration: fire-fighter and/or incendiarist?. Neuropathol. Appl. Neurobiol. (2009)
117. Reixach N., Adamski-Werner S.L., Kelly J.W., Koziol J., and Buxbaum J.N. Cell based screening of inhibitors of transthyretin aggregation. Biochem. Biophys. Res. Commun. 348 (2006) 889-897
118. Rojas Quijano F.A., Morrow D., Wise B.M., Brancia F.L., and Goux W.J. Prediction of nucleating sequences from amyloidogenic propensities of tau-related peptides. Biochemistry 45 (2006) 4638-4652
119. Roof D.J., Adamian M., and Hayes A. Rhodopsin accumulation at abnormal sites in retinas of mice with a human P23H rhodopsin transgene. Invest. Ophthalmol. Vis. Sci. 35 (1996) 4049-4062
120. Sahara N., Maeda S., and Takashima A. Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration. Curr. Alzheimer Res. 5 (2008) 591-598
121. Saliba R.S., Munro P.N., Luthert P.J., and Cheetham M.E. The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation. J. Cell. Sci. 115 (2002) 2907-2918
122. Sandilands A., Hutcheson A.M., Long H.A., Prescott A.R., Vrensen G., Löster J., Klopp N., Lutz R.B., Graw J., Masaki S., Dobson C.M., MacPhee C.E., and Quinlan R.A. Altered aggregation properties of mutant gamma-crystallins cause inherited cataract. EMBO J. 21 (2002) 6005-6014
123. Santhoshkumar P., and Sharma K.K. Inhibition of amyloid fibrillogenesis and toxicity by a peptide chaperone. Mol. Cell. Biochem. 267 (2004) 147-155
124. Selkoe D.J. Folding proteins in fatal ways. Nature 426 (2003) 900-904
125. Shang F., Nowell Jr. T.R., and Taylor A. Removal of oxidatively damaged proteins from lens cells by the ubiquitin-proteasome pathway. Exp. Eye Res. 73 (2001) 229-238
126. Shinohara T., Mulhern M.L., and Madson C.J. Silencing gene therapy for mutant membrane, secretory, and lipid proteins in retinitis pigmentosa (RP). Med. Hypotheses 70 (2008) 378-380
127. Sitia R., and Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 426 (2003) 891-894
128. Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 498 (2001) 204-207
129. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4 (2003) 49-60
130. Subramanian S., Madhavadas S., and Balasubramanian P. Influence of conformational antibodies on dissociation of fibrillar amyloid beta (A beta 1-42) in vitro. Indian J. Exp. Biol. 47 (2009) 309-313
131. Sunde M., Richardson S.J., Chang L., Pettersson T.M., Schreiber G., and Blake C.C. The crystal structure of transthyretin from chicken. Eur. J. Biochem. 236 (1996) 491-499
132. Sung C.H., Davenport C.M., and Nathans J. Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa clustering of functional classes along the polypeptide chain. J. Biol. Chem. 268 (1993) 26645-26649
133. Surgucheva I., McMahan B., Ahmed F., Tomarev S., Wax M.B., and Surguchov A. Synucleins in glaucoma: implication of γ-synuclein in glaucomatous alterations in the optic nerve. J. Neurosci. Res. 68 (2002) 97-106
134. Surgucheva I., Ninkina N., Buchman V.L., Grasing K., and Surguchov A. Protein aggregation in retinal cells and approaches to cell protection. Cell. Mol. Neurobiol. 25 (2005) 1051-1066
135. Surgucheva I., Park B.C., Yue B.Y., Tomarev S., and Surguchov A. Interaction of myocilin with gamma-synuclein affects its secretion and aggregation. Cell. Mol. Neurobiol. 25 (2005) 1009-1033
136. Surguchov A. Molecular and cellular biology of synucleins. Int. Rev. Cytol. Cell Biol. 270 (2008) 225-317
137. Surguchov A., McMahon B., Masliah E., and Surgucheva I. Synucleins in ocular tissues. J. Neurosci. Res. 65 (2001) 68-77
138. Tai T.Y., Damani M.R., Vo R., Rayner S.A., Glasgow B.J., Hofbauer J.D., Casey R., and Aldave A.J. Keratoconus associated with corneal stromal amyloid deposition containing TGFBIp. Cornea 28 (2009) 589-593
139. Tompa P. Intrinsically unstructured proteins evolve by repeat expansion. BioEssays 25 (2003) 847-855
140. Travis G.H., Groshan K.R., Lloyd M., and Bok D. Complete rescue of photoreceptor dysplasia and degeneration in transgenic retinal degeneration slow (rds) mice. Neuron 9 (1992) 113-119
141. Truscott R.J.W. Eye lens proteins and cataracts. In: Fink A.L., and Uversky V.N. (Eds). Protein Misfolding, Aggregation and Conformational Disease, Part B vol. 6 (2007), Springer 435-447
142. Uversky V.N. Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 11 (2002) 739-756
143. Uversky V.N. Protein folding revisited A polypeptided chain at the folding-misfolding-non-folding cross-roads: which way to go?. Cell. Mol. Life Sci. 60 (2003) 1852-1871
144. Uversky V.N. Amyloidogenesis of naturally unfolded proteins. Curr. Alzheimer's Res. 5 (2008) 260-267
145. Uversky V.N., and Fink A.L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 1698 (2004) 131-153
146. Uversky V.N., Gillespie J.R., and Fink A.L. Why are "natively unfolded" proteins unstructured under physiologic conditions?. Proteins 41 (2000) 415-427
147. Uversky V.N., Li J., and Fink A.L. Pesticides directly accelerate the rate of alpha synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 500 (2001) 105-108
148. Uversky V.N., Radivojac P., Iakoucheva L.M., Obradovic Z., and Dunker A.K. Prediction of intrinsic disorder and its use in functional proteomics. Methods Mol. Biol. 408 (2007) 69-92
149. Vemuganti G.K., and Mandal A.K. Subepithelial corneal amyloid deposits in a case of congenital glaucoma. Cornea 21 (2002) 315-317
150. Walker L.C., and LeVine H. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol. Neurobiol. 21 (2000) 83-95
151. Walker L.C., LeVine H., Mattson M.P., and Jucker M. Inducible proteopathies. TINS 29 (2006) 438-443
152. Ward C.L., Omura S., and Kopito R.R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83 (1995) 121-127
153. Westerheide S.D., Bosman J.D., Mbadugha B.N., Kawahara T.L., Matsumoto G., Kim S., Gu W., Devlin J.P., Silverman R.B., and Morimoto R.I. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem. 279 (2004) 56053-56060
154. Wisniewski T., and Sadowski M. Preventing β-amyloid fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors. BMC Neurosci. 9 Suppl. 2 (2008) S5
155. Yam G.H., Gaplovska-Kysela K., Zuber C., and Roth J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest. Ophthalmol. Vis. Sci. 48 (2007) 1683-1690
156. Yoneda S., Hara H., Hirata A., Fukushima M., Inomata Y., and Tanihara H. Vitreous fluid levels of beta-amyloid (1-42) and tau in patients with retinal diseases. Jpn. J. Ophthalmol. 492 (2005) 106-108
157. Yoshida T., Ohno-Matsui K., Ichinose S., Sato T., Iwata N., Saido T.C., Hisatomi T., Mochizuki M., and Morita I. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J. Clin. Invest. 115 (2005) 2793-2800
158. Zhang J., Yan H., Harding J.J., Liu Z.X., Wang X., and Ruan Y.S. Identification of the primary targets of carbamylation in bovine lens proteins by mass spectrometry. Curr. Eye Res. 33 (2008) 963-976
159. Zólyomi Z., Benson M.D., Halász K., Uemichi T., and Fekete G. Transthyretin mutation (serine 84) associated with familial amyloid polyneuropathy in a Hungarian family. Amyloid 5 (1998) 30-34